EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

The Role of Abatacept on Inflammation and Fibrosis in Hypochlorous Acid‐Induced Fibrosis Mice

Bingying Dai iD, Meng Meng, Weilin Chen, Junyu Zhou, Qiming Meng, Liqing Ding, Shasha Xie, Ding Bao, Xiaojing Li, Lijuan Zhao, Ting Huang, Chunliu Lv und 3 weitere

International Journal of Rheumatic Diseases · 2025

DOI: 10.1111/1756-185x.70250 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Rheumatic Diseases, 2025. Verfasst von Bingying Dai und 14 weiteren Autor:innen. Beteiligte Einrichtung: The Department of Rheumatology and Immunology, Xiangya Hospital of Central South University, Changsha, People's Republic of China. Hauptthemen laut MEDLINE: Abatacept, Hypochlorous Acid, Skin, Lung. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Natural Science Foundation of Hunan Province, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To investigate the effect of abatacept in the hypochlorous acid (HCLO)‐induced fibrosis model and to analyze changes in immune cell fractions within the abatacept‐treated early diffuse systemic sclerosis (SSc) cohort.

Methods

Fibrosis was induced in BALB/c mice by subcutaneous injection of HCLO, and abatacept was injected intraperitoneally on alternate days starting on day 28. After 6 weeks, we assessed the pathological changes, inflammation, myofibroblast activation, and the percentage of ICOS in CD3+ T cells. Potential pathways affected by abatacept were also investigated. Finally, we analyzed immune infiltration and multiple scores in early diffuse SSc patients and in the skin and lung tissues of the HCLO model after abatacept administration.

Results

Abatacept significantly decreased the proportion of M2 macrophages in the abatacept‐treated HCLO model and the inflammatory improver subset of SSc patients. Furthermore, abatacept reduced CD28 signaling, the inflammation‐related pathway, and the ICOS expression on CD3+ T cells in HCLO mice. In the inflammatory subset of SSc patients and HCLO mice, microenvironmental and immune scores tended to decrease after abatacept treatment. Unexpectedly, abatacept had no effect on skin or lung collagen content in HCLO mice. The number of T cells and myofibroblasts was not reduced in the abatacept‐treated HCLO group.

Conclusion

Although abatacept did not improve skin and lung fibrosis in the HCLO mice, it reduced the immune response signature and the proportion of M2 macrophages. These findings suggest that further research is needed to assess the therapeutic value of abatacept in SSc patients and preclinical mouse models.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AbataceptHypochlorous AcidSkinLungScleroderma, SystemicInflammationAnimalsMice, Inbred BALB CDisease Models, AnimalHumansFibrosisFemaleMacrophagesMaleMiceT-LymphocytesMiddle Aged

Stichwörter der Autor:innen

HCLO‐induced fibrosis modelRNA‐seqabataceptimmune infiltrationsystemic sclerosis

Substanzen

AbataceptHypochlorous Acid

Autor:innen und Institutionen

  • The Department of Rheumatology and Immunology, Xiangya Hospital of Central South University, Changsha, People's Republic of China.
  • Department of Pathology, Xiangya Hospital, Changsha, People's Republic of China.
  • Department of Breast Tumor Plastic Surgery, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, People's Republic of China.
  • Provincial Clinical Research Center for Rheumatic and Immunologic Diseases, Xiangya Hospital, Changsha, People's Republic of China.
  • National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Changsha, People's Republic of China.

ORCID-Profile: Bingying Dai

Förderung

  • Natural Science Foundation of Hunan Province
  • National Natural Science Foundation of China

Zitieren

APA

Dai, B., Meng, M., Chen, W., Zhou, J., Meng, Q., Ding, L., Xie, S., Bao, D., Li, X., Zhao, L., Huang, T., Lv, C., Luo, H., Liu, S., & Zhu, H. (2025). The Role of Abatacept on Inflammation and Fibrosis in Hypochlorous Acid‐Induced Fibrosis Mice. International Journal of Rheumatic Diseases. https://doi.org/10.1111/1756-185x.70250

Vancouver

Dai B, Meng M, Chen W, Zhou J, Meng Q, Ding L, et al. The Role of Abatacept on Inflammation and Fibrosis in Hypochlorous Acid‐Induced Fibrosis Mice. International Journal of Rheumatic Diseases. 2025. doi:10.1111/1756-185x.70250

BibTeX
@article{Dai2025,
  author = {Dai, Bingying and Meng, Meng and Chen, Weilin and Zhou, Junyu and Meng, Qiming and Ding, Liqing and Xie, Shasha and Bao, Ding and Li, Xiaojing and Zhao, Lijuan and Huang, Ting and Lv, Chunliu and Luo, Hui and Liu, Sijia and Zhu, Honglin},
  title = {The Role of Abatacept on Inflammation and Fibrosis in Hypochlorous Acid‐Induced Fibrosis Mice},
  journal = {International Journal of Rheumatic Diseases},
  year = {2025},
  doi = {10.1111/1756-185x.70250}
}
Kostenlos starten →